Do nK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma?
IL-15 and CpG ODN A enhance rituximab-mediated ADCC against B-cell lymphoma. Under these conditions, NK cells seem to be the main effector cells mediating ADCC. These findings suggest that these agents could be used as adjuvants in combination with rituximab for patients with B-cell lymphoma.
GIR was rather variable and not proportional to clamped plasma glucose levels. MCR was a less variable parameter than GIR at various plasma glucose levels, and MCR at FPG in the isoglycemic clamp study could be substituted for GIR at the euglycemic clamp study.